MACAU DAILY TIMES 澳門每日時報

Top Menu

  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia

Main Menu

  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia
logo
FOUNDER & PUBLISHER Kowie Geldenhuys
EDITOR-IN-CHIEF Paulo Coutinho
Macau,

MACAU DAILY TIMES 澳門每日時報

  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • 1 in 14 residents has diabetes, SSM survey finds

  • Grand Prix opens with citywide cultural festival

  • Gov’t launches cross-border elderly care pilot with 50 places in Zhuhai

  • 39 land parcels earmarked for temporary public facilities

  • Grand Prix road closures to disrupt 51 bus routes

  • Southeast Asian leaders open annual summit with major conflicts and their impact topping the agenda 

OpinionThe Conversation
Home›Opinion›THE CONVERSATION | Sinopharm and Sinovac vaccines: How effective are they?

THE CONVERSATION | Sinopharm and Sinovac vaccines: How effective are they?

By -
Wednesday, September 29, 2021
118
0

John Hart
Clinical researcher, Murdoch Children’s Research Institute

Fiona Russell
Senior Principal Research Fellow; pediatrician; infectious diseases epidemiologist, The University of Melbourne

In June, China reached a milestone of having administered more than one billion doses of its homegrown COVID-19 vaccines [currently over two billion], the majority of which were developed by local companies Sinovac and Sinopharm.
What’s more, hundreds of millions of doses of these vaccines have been shipped to more than 80 countries worldwide.
Sinopharm was given emergency approval by the World Health Organization (WHO) in May this year, and Sinovac in June.
But what do we know about these vaccines? How do they work, are they safe, and how effective are they in the real world?

What type of vaccine are they?
Both are inactivated virus vaccines. This means they’re made from viral particles produced in a lab, which are then inactivated so they can’t infect you with COVID-19. Many other vaccines use similar platforms, including injectable polio, Hepatitis A and flu vaccines.
Both companies use similar technology, and the vaccines are mixed with an adjuvant, which is a substance added to vaccines to stimulate a stronger immune response.
The vaccines contain many proteins the immune system can respond to, stimulating the production of antibodies to fight COVID-19.

Are they safe?
Side-effects common after most other COVID-19 vaccines, such as fever and fatigue, were found to be uncommon after Sinovac or Sinopharm.
Once vaccines are approved and being used in large populations, they’re continuously monitored for very rare side effects. No significant safety concerns have been identified amid Sinovac’s rollout in China, Brazil, Indonesia and Chile.
In saying that, there were very low numbers of adverse events identified overall, which would suggest substantial under-reporting.
For example, there were only 49 serious adverse events reported following 35.8 million Sinovac doses administered in China.
In a population of that size, we’d expect to see a larger number of illnesses and deaths recorded in the few weeks after vaccination just by coincidence alone, even if not causally related to the vaccine.
Only 79 people reported mostly mild adverse events following 1.1 million doses of Sinopharm in China, much lower than usual rates of adverse event reporting following immunisation.
A potential side effect of particular concern is what’s called “vaccine-associated enhanced disease”. This is a very rare side effect of some other vaccines which use a similar “inactivated” technology to the Sinopharm and Sinovac vaccines.
It occurs when a vaccinated person is exposed to the virus and develops a serious inflammatory condition, and results in them getting more severe symptoms than they would have without the vaccination.
This hasn’t been reported for these vaccines to date, although WHO recommends ongoing safety monitoring to identify any cases that occur.

What was their efficacy in clinical trials?
Sinovac’s efficacy at preventing symptomatic infection was 51% in Brazil, 67% in Chile, 65% in Indonesia, and 84% in Turkey. The differences in results may be due to different variants circulating in each country at the time and differences in the populations included in the studies.
Sinopharm’s efficacy in preventing symptomatic infection was 78% in UAE, Bahrain, Egypt and Jordan combined.
As with all the COVID-19 vaccines for which data are available, efficacy against the more severe outcomes is greater. Efficacy against hospitalisation for Sinovac in Chile, Brazil and Turkey was 85%, 100% and 100%, respectively.
However, few elderly people with underlying health issues were enrolled into these studies.
For Sinopharm, efficacy against hospitalization was 79%, although few women were enrolled in these studies.

How effective are they in the real world?
Data published in April from a large real-world study in Chile suggests Sinovac is 67% effective in preventing symptomatic COVID-19 infection. It’s effectiveness against hospitalisation was 85%, ICU admission 89%, and death 80%.
Sinopharm’s effectiveness against symptomatic infection in Bahrain was 90%.
However, it’s concerning there have been increases in infections in some countries where these vaccines have been extensively used, but detailed reports are not available.
For example, Seychelles has fully vaccinated 68% of its population, mostly with Sinopharm and the remainder with AstraZeneca.
Seychelles has recently experienced a surge in cases, which suggests the herd immunity threshold may not have been reached. The exact threshold for this is unknown but is influenced by variants in circulation, the number of people vaccinated, and the effectiveness of the vaccines.
Detailed epidemiological studies are required to investigate this but news reports suggest 20% of those hospitalised and 37% of new active cases are fully vaccinated.
Bahrain and the United Arab Emirates have also achieved high vaccination coverage, predominantly with Sinopharm. They also experienced recent COVID-19 surges, and are offering a booster dose of Pfizer six months after two Sinopharm doses, because of concerns two doses of Sinopharm may not provide sufficient protection.
However, there’s no data publicly available to determine whether this mix and match schedule is safe and produces a protective immune response.
In Mongolia, the rapid vaccine rollout of four different vaccines, including Sinopharm, suggests initial good effectiveness but an increase in cases suggests short-term protection only, and perhaps little effect on transmission.
Also, in June, there increasing concerns about surging cases in Indonesia. Almost all health workers have been vaccinated with the Sinovac vaccine but some developed severe disease.
Chile has also achieved high vaccine coverage, mostly with Sinovac. Around 75% of the adult population has received one dose, and 58% two doses.
Despite this, a surge in infections and consistent high numbers of deaths, in June, has prompted a blanket lockdown across the capital, Santiago. The spread may be related to the more transmissible Gamma variant, which first emerged in Brazil.
However, in a small town of 45,000 in Brazil, very high vaccination coverage with Sinovac of 95% of adults, reportedly decreased symptomatic infections by 80% and deaths by 95%.
There’s currently no data on how effective Sinopharm is against any variant of concern despite its use in more than 50 countries.
For Sinovac, effectiveness against symptomatic infection with the Alpha and Gamma variants in Chile was 67%.
In Brazil, with circulation of the Gamma variant, one pre-print study suggested effectiveness against symptomatic infection was 42%.
Both vaccines are effective against severe COVID-19.
However, it is critical that researchers and health authorities determine vaccine effectiveness against variants and their effect on transmission, and their safety profiles. For countries that have community transmission this includes “vaccine-associated enhanced disease”.
As for any vaccine, we also need to understand how effective these vaccines are in older people, adolescents, pregnant women and immunocompromised groups, and how long protection lasts.
We need as many vaccines as possible to tackle the pandemic. But now these vaccines are in widespread use and will be further distributed by COVAX, a global alliance which provides vaccine doses to low-and middle-income nations, it’s essential the safety and effectiveness of all vaccines continues to be closely monitored. MDT/THE CONVERSATION

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Print (Opens in new window) Print

Like this:

Like Loading…

Related

TagsThe Conversation
Previous Article

Neighborhoods of three new cases placed under ...

Next Article

Thursday, September 30, 2021 – edition no. ...

Related articles More from author

  • World

    Experts urge parents to prepare kids for possible livestreamed execution

    Wednesday, October 14, 2026
    By MDT/AP
  • OpinionThe Conversation

    What we forget when we remember 9/11

    Friday, September 11, 2026
    By -
  • HeadlinesThe Conversation

    Trump’s indictment stretches US legal system in new ways – a former prosecutor explains four key points to understand

    Monday, April 3, 2023
    By -
  • OpinionThe Conversation

    Quran burning in Sweden prompts debate on freedom of expression vs incitement of hatred

    Thursday, August 31, 2023
    By -
  • OpinionThe Conversation

    What’s the point of giving gifts? An anthropologist explains this ancient part of being human

    Friday, December 22, 2023
    By -
  • OpinionThe Conversation

    High interest rates aren’t going away anytime soon

    Friday, May 3, 2024
    By -

  • HeadlinesMacau

    11-year-old girl duped in fake mainland police scam

  • World

    World briefs

  • Daily Edition

    Monday, October 20, 2014 – edition no. 2173

DAILY EDITION

Monday, November 16, 2026 – edition no. 5075
Monday, November 16, 2026 – edition no. 5075

Greater Bay

MDT MACAU GRAND PRIX SPECIAL

November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« Oct    

Timeline

  • Monday, November 16, 2026

    1 in 14 residents has diabetes, SSM survey finds

  • Monday, November 16, 2026

    Grand Prix opens with citywide cultural festival

  • Monday, November 16, 2026

    Gov’t launches cross-border elderly care pilot with 50 places in Zhuhai

  • Monday, November 16, 2026

    39 land parcels earmarked for temporary public facilities

  • Monday, November 16, 2026

    Grand Prix road closures to disrupt 51 bus routes

  • Monday, November 16, 2026

    Southeast Asian leaders open annual summit with major conflicts and their impact topping the agenda 

  • Monday, November 16, 2026

    Creative industries need creative people

  • Monday, November 16, 2026

    Strictly upholding the bottom line of the rule of law and safeguarding its core values

  • Monday, November 16, 2026

    Strictly adhering to statutory procedures; Safeguarding national security interests

  • Monday, November 16, 2026

    21 more school and nursery entrances designated smoke-free

Extra Times

Extra TimesHeadlinesTaste of Edesia

Three chefs. One horizon. Six Michelin stars

There are moments when separate culinary philosophies align so precisely that the result transcends mere menu-making. At Chef Tam’s Seasons, Wynn Palace, three two-Michelin-starred titans—each ranked among Asia’s 50 Best ...
  • James Gray delivers a milestone crime drama in ‘Paper Tiger’

    By MDT/AP
    Friday, November 13, 2026
  • The Twelve25 × La Vie exchange

    By -
    Friday, November 13, 2026
  • A fiery milestone: Feng Wei Ju’s 20th anniversary tribute to Starworld Macau

    By Irene Sam, MDT
    Friday, November 6, 2026
  • In ‘I Play Rocky,’ a middleweight crowd-pleaser about the making of a classic

    By MDT/AP
    Friday, November 6, 2026
  • Recent

  • Popular

  • 1 in 14 residents has diabetes, SSM survey finds

    By Nadia Shaw, MDT
    Monday, November 16, 2026
  • Grand Prix opens with citywide cultural festival

    By Renato Marques, MDT
    Monday, November 16, 2026
  • Gov’t launches cross-border elderly care pilot with 50 places in Zhuhai

    By Yuki Lei, MDT
    Monday, November 16, 2026
  • 39 land parcels earmarked for temporary public facilities

    By Yuki Lei, MDT
    Monday, November 16, 2026
  • Grand Prix road closures to disrupt 51 bus routes

    By Nadia Shaw, MDT
    Monday, November 16, 2026
  • Southeast Asian leaders open annual summit with major conflicts and their impact topping the agenda 

    By -
    Monday, November 16, 2026
  • Creative industries need creative people

    By Renato Marques, MDT
    Monday, November 16, 2026
  • Canidrome may have its days numbered, decision in ‘one or two months’

    By Paulo Coutinho, MDT
    Thursday, May 26, 2016
  • Animal Welfare | Macau: Anima slams Canidrome management for avoiding debate

    By -
    Wednesday, May 4, 2016
  • Editorial | Canidoomed

    By Paulo Coutinho, MDT
    Wednesday, June 1, 2016
  • Animal Welfare | Canidrome presented with ultimatum: close or move

    By Daniel Beitler, MDT
    Friday, July 22, 2016
  • Australia regulator cracks down on alleged exportation of dogs to Macau

    By Paulo Coutinho, MDT
    Friday, June 10, 2016
  • Animal rights | Canidrome: Anima in fresh airline negotiations as Canidrome closure looks more likely

    By Daniel Beitler, MDT
    Friday, May 27, 2016
  • USE OF ENGLISH IN MACAU | A ‘de facto’ official language

    By Catarina Pinto
    Monday, July 6, 2015
  • Contact our Administrator
  • Contact our Editor-in-Chief
  • Contacts
  • Our Team
  • Privacy Policy
  • Terms and Conditions
  • Editorial Statute
  • Code of Ethics
COPYRIGHT © MACAU DAILY TIMES 2008-2026. ALL RIGHTS RESERVED
MACAU DAILY TIMES
  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia
Loading Comments...

You must be logged in to post a comment.

%d